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Abstract
Although Clostridium difﬁcile (C. difﬁcile) is the leading cause of infectious diarrhoea in hospitalized patients, the economic burden of this
major nosocomial pathogen for hospitals, third-party payers and society remains unclear. We developed an economic computer simula-
tion model to determine the costs attributable to healthcare-acquired C. difﬁcile infection (CDI) from the hospital, third-party payer and
societal perspectives. Sensitivity analyses explored the effects of varying the cost of hospitalization, C. difﬁcile-attributable length of stay,
and the probability of initial and secondary recurrences. The median cost of a case ranged from $9179 to $11 456 from the hospital
perspective, $8932 to $11 679 from the third-party payor perspective, and $13 310 to $16 464 from the societal perspective. Most of
the costs incurred were accrued during a patient’s primary CDI episode. Hospitals with an incidence of 4.1 CDI cases per 100 000 dis-
charges would incur costs ‡$3.2 million (hospital perspective); an incidence of 10.5 would lead to costs ‡$30.6 million. Our model sug-
gests that the annual US economic burden of CDI would be ‡$496 million (hospital perspective), ‡$547 million (third-party payer
perspective) and ‡$796 million (societal perspective). Our results show that C. difﬁcile infection is indeed costly, not only to third-party
payers and the hospital, but to society as well. These results are consistent with current literature citing C. difﬁcile as a costly disease.
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Introduction
Although Clostridium difﬁcile (C. difﬁcile) is a major nosocomial
pathogen and leading cause of infectious diarrhoea in hospi-
talized patients [1–3], its economic burden has not been fully
characterized. Several retrospective studies and one prospec-
tive study have examined the healthcare costs of C. difﬁcile
[1,4–10]. However, these studies explored speciﬁc cases or
types of patients (e.g. IBS patients, surgical patients, intensive
care unit (ICU) patients, or adults in tertiary care hospitals)
and therefore may not be generalizable to other hospitals
and circumstances. Moreover, their methodologies and
included costs varied, as cost evaluation was not a priority
for most. Separate systematic reviews by Dubberke et al.
and Ghantoji et al. cite the limitations of these studies and
call for a more accurate and comprehensive report of the
true economic burden of C. difﬁcile infection (CDI) [1,6].
Better understanding of the economic burden of C. difﬁcile
can assist various decision makers. Hospital administrators,
infection control practitioners and policy makers could use
this information to determine how much to invest in C. difﬁ-
cile prevention and control measures. This information can
help policy makers and third-party payers to make insurance
coverage and reimbursement decisions. These reimburse-
ment decisions may change as Centers for Medicare and
Medicaid Services rules evolve. Manufacturers and drug com-
panies can use such information to develop and price C. difﬁ-
cile tests and treatments. We developed an economic
computational simulation model to determine the cost of
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healthcare-acquired CDI (for the duration of hospitalization)
from the perspective of various decision makers and deter-
mine the annual United States (US) burden. Sensitivity analyses
varied the key parameters of attributable length-
of-stay (LOS), probability of ﬁrst and second recurrences,
and hospitalization cost.
Methods
Using TreeAgo Pro 2009 (Williamstown, MA, USA) we con-
structed a stochastic computer simulation model to deter-
mine the additional costs associated with healthcare-acquired
CDI from the hospital, third-party payer and societal perspec-
tives. We also determined the annual burden of hospital-
acquired C. difﬁcile in US hospitals and across the country.
Fig. 1 shows the basic model structure. Patients were the
typical age of CDI patients (‡65 years old) [2,11]. An infected
patient could have either mild or severe CDI. All patients had
a probability of having recurrent CDI over the course of a
year. Patients with severe CDI could progress to fulminant
C. difﬁcile, which required hospitalization in the ICU. Those
with fulminant CDI could undergo surgery (i.e. total colecto-
my) or not undergo surgery, each accompanied with its own
probability of death. This ﬁrst CDI occurrence was experi-
enced by all patients in the model. Recurrences could be
either mild or severe, resulting in rehospitalization. Up to two
CDI recurrences could occur in 1 year for a total of three
possible episodes per patient, resulting in a progressively
smaller fraction of patients that experienced any recurrence.
Treatment options differed by disease severity, prior
treatments and number of recurrences. Patients with mild
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FIG. 1. General decision model tree structure. *Give Tapered Vanomycin. eUse treatment strategy that was effective for prior episode. Treat-
ment change: from metronidazole to vancomycin; no treatment change for vancomycin.
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CDI received metronidazole (500 mg, three times a day for
10–14 days [2,3]) as a ﬁrst-line antibiotic treatment and
vancomycin if two courses of metronidazole failed. Patients
with severe disease received vancomycin (125 mg, four times
as day for 10–14 days [2,3]) as a ﬁrst-line antibiotic treat-
ment and received another course if the ﬁrst failed. Patients
with fulminant infection received vancomycin prior to sur-
gery. In the event of a recurrence, the ﬁrst-line treatment
was the same antibiotic that worked for the initial episode as
resistance to both drugs remains fairly low [3,12]. A tapered
course of vancomycin (four times a day for 14 days, two
times a day for 7 days, once a day for 7 days, once every
2 days for 8 days, once every 3 days for 15 days [2,3]) was
used to treat patients with ‡2 recurrences. Additionally,
patients who were candidates for surgery (i.e. fulminant CDI
patients) had an abdominal computerized tomography CT
scan performed to determine if surgery should occur; those
proceeding to surgery required an additional peripheral
intravenous line insertion and received metronizadole intra-
venously (500 mg, every 8 h for 10–14 days [2,3]) in addition
to oral vancomycin.
To determine the cost of a healthcare-acquired CDI case,
each simulation sent 1000 adults (‡65 years old) through the
model 1000 times for 1 000 000 total unique cost outcomes.
The three different perspectives accounted for different
combinations of costs.
1 Hospital perspective: determined the opportunity cost of
lost hospital bed days from an extended hospital LOS
caused by CDI adapting a method described by Graves
(extended LOS occupies beds that could have been used
by other patients, costing hospitals potential revenue)
[13]. This lost revenue for each case was determined by
the cost of a bed-day for each CDI-attributable additional
LOS day for each episode.
2 Third-party payer perspective: included only the direct costs
of illness, such as the cost of hospitalization, diagnosis,
treatment and surgery.
3 Societal perspective: included both direct (those included
in the third-party payer perspective) and indirect costs.
Indirect costs included productivity losses for the dura-
tion of illness (i.e. time missed from work for those
working and/or caregivers and lost contributions to soci-
ety for those retired) and lifelong productivity losses (i.e.
lost wages from death for a patient 65 years old). Pro-
ductivity losses due to illness were derived from wages
lost for the LOS for each episode (not beyond) and
those due to mortality were calculated from the annual
wages lost for the years of life lost outlined by the
Human Mortality Database [14], discounted 3% per year.
We did not include any costs incurred after hospital dis-
charge.
Data inputs
Table 1 lists the model inputs with their corresponding val-
ues, distribution types and sources. All costs were converted
to 2010 $US using a 3% annual discount rate [15].
TABLE 1. Model input parameters
Description (units)
Model
perspective
Distribution
type Mean SD or range Source
Costs ($US)
Median hourly wage S 16.43 25
Mean annual wage S 44 764 25
Hospitalization T, S Gamma 7767.70 322.19 11
Bed day H Gamma 1220.30 53.70 11
ICU bed day H Triangular 4398 1000–8000 26
Peripheral intravenous line insertion T, S 96.98 27
CT scan T, S Gamma 276.10 29.61 27
Antibiotics (full course)
Metronidazole (IV) T, S Gamma 112.97 10.56 28
Metronidazole (oral) T, S Gamma 55.74 37.49 28
Vancomycin (oral) T, S Gamma 1308.15 75.26 28
Vancomycin (tapered) T, S Gamma 2008.94 115.57 28
Colectomy T, S Gamma 35 161.46 3905.92 11
All-cause mortality T, S Triangular 6921 5191–9025 29
Probabilities (%)
Given C. difﬁcile infection
Severe disease All Beta 17.8 4.06 30–33
Fulminant disease (ICU) All Uniform 3.0–8.0 34,35
Fulminant mortality All 80.5 36,37
Recurrence All Beta 18.9 6.77 33,38,39
Colectomy All Beta 40.92 24.43 37,40
Mortality from colectomy All Beta 41.60 7.85 34,37,40–42
C. difﬁcile treatment efﬁcacies
Metronidazole All Beta 87.7 5.22 3,43,44
Vancomycin All Beta 97.1 0.13 3,44
Vancomycin (tapered) All Triangular 68.97 45.52–92.41 45
H, hospital perspective; T, third-party payer perspective; S, societal perspective.
All, denotes parameters used from the hospital, third-party payer and societal perspectives.
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Sensitivity analyses
Sensitivity analyses ranged key variables to determine their
effects on CDI cost. We varied hospitalization cost from
baseline (mean, $7 767.70 [11]) to baseline ±$1000 (SD
times three). The probability of secondary recurrences has
been debated in the literature and was varied from 20%
(same as primary recurrences) to a distribution ranging from
33 to 45% (likeliest, 40%) [2,16]. An additional set of sensi-
tivity analyses varied the ﬁrst recurrence probability
(10–30%) and secondary recurrence probability (30–50%).
CDI-attributable additional LOS for severe and fulminant
CDI episodes was ranged from 6 to 14 days ([11,17] and
expert opinion); all mild episodes had a CDI-attributable
LOS of 6 days. Additionally, probabilistic sensitivity analyses
simultaneously varied all parameters throughout their ranges
in Table 1.
Results
Table 2 shows the median cost and 95% conﬁdence interval
(CI) for all perspectives and scenarios explored. The cost of
a healthcare-acquired CDI case ranged from $8932 to
$16 464. Fig. 2 shows the impact that varying the model
parameters over the ranges explored through our sensitivity
analysis has on CDI’s burden.
Hospital perspective
Assuming all CDI cases had a 6-day CDI-attributable addi-
tional LOS, one CDI case cost a median $9197 (CI, $7833–
$11 047). When the severe and fulminant CDI cases experi-
enced a 10-day CDI-attributable additional LOS, the cost
was $10 187 (Table 2). Increasing the probability of second-
ary recurrences (likeliest, 40%) increased costs, but did not
have a large effect (range, $9401–$11 456). Compared with
the baseline recurrence rate (18.9%), varying the ﬁrst (10–
30%) and second (30–50%) recurrence probabilities did not
substantially affect CDI costs (range, $8438–$10 795 for 6-
day LOS; data not shown) as relatively few patients experi-
enced a recurrence. Fig. 2(a) shows which variables had the
largest effect on CDI cost.
Most of the burden was attributed to a patient’s ﬁrst CDI
occurrence, with median cost $7511 (CI, $6868–$8210),
$8485 (CI, $7562–$9427) and $9539 (CI, $8342–$10 994)
for a 6, 10 and 14-day CDI-attributable additional LOS,
respectively (data not shown).
Third-party payer perspective
As Table 2 shows, one CDI case from the third-party payer
perspective cost a median $10 123 (CI, $8711–$12 369) at
baseline. Increasing the probability of secondary recurrences
(likeliest, 40%) had a marginal effect on cost (median,
$10 499; CI, $8983–$12 722). Varying hospitalization cost
had an effect on CDI cost. Decreasing hospitalization cost by
$1000 resulted in median costs of $8932 and increasing by
$1000 resulted in a cost of $11 386 (Table 2). Changing ﬁrst
and second recurrence probabilities resulted in costs ranging
from $9392 (ﬁrst recurrence probability 10%, probability
second recurrence 30%) to $12 257 (30% ﬁrst recurrence
rate, 50% second recurrence rate) at the baseline hospitaliza-
tion cost (data not shown). Even though these costs were
similar to those at the baseline recurrence rate (18.9%),
TABLE 2. Incremental cost of Clos-
tridium difﬁcile infection from each
perspective for baseline and an
increased secondary recurrence
rate
Scenario
Baseline secondary
recurrence rateb
Increased secondary
recurrence ratec
Median 95% CI Median 95% CI
Hospital perspective
6-day LOS 9179 7833–11 047 9401 8063–11 136
10-day LOS 10 187 8684–12 249 10 424 8873–12 466
14-day LOS 11 175 9398–13 651 11 456 9511–13 709
Third-party payer perspective
Baseline)$1000 8932 7542–10 865 9188 7838–11 056
Baseline costa 10 123 8711–12 369 10 499 8983–12 722
Baseline + $1000 11 386 9837–13 820 11 679 10 107–13 983
Societal perspective
Baseline)$1000, 6-day LOS 13 310 9431–19 840 13 740 9730–19 508
Baseline)$1000, 10-day LOS 13 589 9843–19 116 13 783 9967–20 204
Baseline)$1000, 14-day LOS 13 511 9832–19 740 13 851 9857–20 573
Baseline, 6-day LOS 14 726 10 491–20 724 14 926 10 853–21 500
Baseline, 10-day LOS 14 732 10 578–20 849 15 213 11 067–21 743
Baseline, 14-day LOS 14 783 10 662–21 065 15 257 11 334–21 878
Baseline + $1000, 6-day LOS 15 810 11 790–21 967 16 271 11 997–23 065
Baseline + $1000, 10-day LOS 15 851 11 752–22 541 16 355 12 082–23 245
Baseline + $1000, 14-day LOS 16 078 11 862–22 110 16 464 12 139–23 019
aBaseline cost = mean, $7767.70 (SD, $322.19).
bBaseline secondary recurrence rate = mean, 18.9% (SD, 6.77%).
cIncreased secondary recurrence rate = range, 33–45% (likeliest, 40%).
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changing the ﬁrst recurrence probability did have a substan-
tial effect on cost. Fig. 2(b) shows the major cost drivers.
A major portion of these costs occurred during a patient’s
ﬁrst episode. The primary episode cost $8237 (CI, $7563–
$9014) at baseline hospitalization cost, $7262 with a
decreased hospitalization cost and $9271 with an increased
hospitalization cost (data not shown).
Societal perspective
One CDI case cost $14 726 (CI, $10 491–$20 724) with the
baseline hospitalization cost and 6-day additional LOS for all
CDI patients (Table 2). Across all recurrence rates, lower
hospitalization cost decreased CDI cost (range, $13 740–
$16 079), and higher hospitalization cost increased CDI cost
(range, $15 810–$16 464). Unlike the hospital perspective,
additional LOS did not have much effect (Fig. 2c). Median
costs for a 6-day CDI-attributable additional LOS ranged
from $13 310 (cost, baseline )$1000, baseline recurrence)
to $16 271 (cost, baseline +$1000, increased recurrence).
An increased recurrence rate (likeliest, 40%) yielded higher
costs (median, $14 926; CI, $10 853–$21 500) for CDI cases
at baseline cost and 6-day CDI-attributable additional LOS.
Costs increased for all combinations of hospitalization cost
and additional LOSs at a higher recurrence rate. Although
ranging the ﬁrst (10–30%) and second (30–50%) recurrence
probabilities showed little difference in costs, the ﬁrst recur-
rence probability was a cost driver (Fig. 2c).
Again, most costs were accrued during the primary CDI
episode; at baseline hospitalization cost, costs varied from
$12 339 (6-day LOS) to $12 607 (14-day LOS). The primary
episode cost $11 375 (6-day LOS) to $11 573 (14-day LOS)
at a lower hospitalization cost and $13 149 (all cases 6-day
LOS) to $15 590 (severe and fulminant 14-day LOS) at a
higher hospitalization cost (data not shown).
Hospital burden
A recent multicentre surveillance study determined the inci-
dence of C. difﬁcile in six hospitals across the US using Inter-
national Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM) codes [18]. Table 3 gives the inci-
dence and number of cases for each of their reported hospi-
tals and gives the calculated burden for each. Costs are for
these six hospitals over the study period from each perspec-
tive. Costs from the hospital perspective ranged from
$3.2 million (Hospital D) to $30.6 million (Hospital A) and
are even more substantial with an increased additional LOS
and secondary recurrence rate. From the third-party payer
and societal perspectives, costs are even more substantial,
with an increased hospitalization cost, CDI-attributable addi-
tional LOS, and secondary recurrence rate.
Annual US burden
Table 3 also reports annual CDI costs for the US. In 2008,
the national point prevalence of C. difﬁcile in US hospital inpa-
tients was 1443 out of 110 550 inpatients [19], and would
generate the costs seen in Table 3. In 2008, 54 046 patients
between the ages of 65 and 84 were discharged with a diagno-
sis of C. difﬁcile [11]. Costs would be ‡$496 million (Table 3).
Discussion
To our knowledge, this is the ﬁrst study to develop an
economic model to determine the cost of CDI from
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FIG. 2. Tornado diagrams showing the effect of each variable on the
cost per CDI case from (a) the hospital perspective, (b) the third-
party payer perspective, and (c) the societal perspective.
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different perspectives and demonstrate how cost may vary
with different parameters. As Dubberke et al. and Ghantoji
et al. indicated, most studies that reported CDI costs did
not focus on economic analyses and therefore did not
include several costs, had cost reporting limitations, and
had varying calculation methods and populations (and coun-
try of origin) [1,6]. In addition, several of these studies
were completed before the emergence of the hypervirulent
BI/NAP1 C. difﬁcile strain [1]. This strain has increased in
frequency, severity and morbidity [2], all of which lead to
potentially increased CDI costs for tests, treatment and
procedures.
Our results do fall within the range of previously reported
CDI costs, which range from $2000 to $72 000 per case
[1,6] and vary with coexisting conditions (range, $11 000–
$24 000) [5,7,8]. Regardless of severity, there are signiﬁcant
associated costs, with most incurred during the initial CDI
episode. Even with ﬁrst recurrence rates as low as 10%,
costs were still substantial from all perspectives. Along with
the ﬁrst recurrence probability, additional LOS (hospital per-
spective) and hospitalization costs (third-party payer and
societal perspectives) appeared to be the main CDI cost
drivers. Nationally, Kyne et al. estimated CDI to be a
$1.1 billion annual cost to the US, where as O’Brien et al.
estimated the annual cost to be approximately $3.2 billion
[9,10]. Our estimates are closer to that reported by Kyne
et al.
Compared with other types of infection, C. difﬁcile can be
an expensive pathogen. Acinetobacter baumannii costs range
from $5000 to ‡$44 000 per case [20], one norovirus case
can cost hospitals $6237 [21], vancomycin-resistant entero-
coccal bloodstream infections cost ‡$4000 [22], and methi-
cillin-resistant Staphylococcus aureus can potentially cost
between $5000 and $40 000 [23].
Our model may be conservative about estimating CDI
costs. We only evaluated costs for the hospitalization dura-
tion; costs to third-party payers and society would be higher
if they were captured for a longer duration to include lost
productivity and other treatments. It included only the more
common and less expensive procedures needed for each
condition and excluded relatively rare CDI complications and
exacerbations of co-morbid conditions. Patients with certain
co-morbidities such as IBS or immunosuppressed patients
may have more costly CDI episodes and elderly patients may
be discharged to a nursing home, presenting additional costs.
We did not include costs for potential antimicrobial resis-
tance to vancomycin and its impact on colonization treat-
ment and spread of vancomycin-resistant enterococci. Also,
hospitals may have additional costs if pay for performance
arrangements are in place [24]. Finally, a CDI case may
require enhanced surveillance and requires infection control
measures (e.g. contact isolation precautions) that incur addi-
tional costs not accounted for in the model. Costs may
change if C. difﬁcile becomes more virulent, if resistance
develops, and if it becomes more increasingly common in
the community and younger persons.
Limitations
Models, by nature, are simpliﬁcations and cannot completely
represent every possible event and outcome, nor the full
spectrum of socio-demographic and clinical heterogeneity
among patients. Data inputs for our model derived from dif-
ferent studies of varying quality and were based on published
data only, thus inputs may change as new data emerge. We
also did not consider alternate or new forms of therapy for
CDI, which may vary from clinician to clinician.
TABLE 3. Hospital and annual US
burden (in $millions) from each
perspective
Population
Incidence
(per 1000
inpatients)
Number
of cases
Burden by perspective (in $ US millions)
Hospital
Third-party
payer Societal
Hospital burdena
Hospital A 10.5 3334 30.6 33.7 49
Hospital B 8.3 915 8.3 9.3 13.5
Hospital C 4.9 1253 11.5 12.7 18.5
Hospital D 4.1 345 3.2 3.5 5.1
Hospital E 8.6 1404 12.9 14.2 20.7
Annual US burden
US Hospital inpatientsb 13.1 1443 13 15 21
Diagnosis of CDI (Patients
aged 65–84 years)c
– 54 046 496 547 796
Hospital perspective: 6-day CDI-attributable LOS and baseline secondary recurrence rate. Third-party payer perspec-
tive: baseline hospitalization cost. Societal perspective: baseline hospitalization cost and 6-day CDI-attributable LOS.
Incidence trends for CDI for each hospital can be found in Dubberke et al.
aSource: Dubberke et al. [18].
bSource: Jarvis et al. [19].
cSource: HCUP facts and ﬁgures: statistics on hospital-based care in the United States, 2008 [http://www.hcup-
us.ahrq.gov/reports.jsp, 11].
CMI McGlone et al. Economic burden of C. difﬁcile 287
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 282–289
Conclusions
Our study quantiﬁes the substantial costs of hospital-
acquired CDI from the hospital, third-party payer and socie-
tal perspectives. Most costs incurred were accrued during a
patient’s primary episode of CDI, with costs as much as
$12 607 (14-day LOS, baseline hospitalization cost from the
societal perspective). Varying the secondary recurrence
probability showed little affect on costs, as they occurred in
relatively few patients. Costs may change if CDI becomes
increasingly common in the community. Efforts to prevent
CDI, through infection control, vaccine development or new
therapies may have the potential to be cost-saving as they
may reduce CDI’s incidence, duration, severity and transmis-
sion.
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